The American pharmaceutical company will stop supplying Zepatir to Russia
[ad_1]
The American pharmaceutical company MSD has stopped supplying Russia with the hepatitis C drug Zepatier. This was reported by Kommersant newspaper with reference to Roszdravnadzor.
As explained in the service, the company is obliged to notify about the termination of deliveries at least one hour before the actual stop of imports. MSD’s letter emphasizes that this decision will not affect deliveries planned for 2024.
According to the newspaper, zepatir accounts for almost 20 percent of all state purchases of drugs for hepatitis C, more than 1 billion rubles are spent on it annually. There are no analogues of the drug in Russia yet. There are other drugs on the market, but Zepatir is one of the most affordable treatment regimens.
In 2022, MSD began to reduce cooperation with Russia: deliveries of the vaccine against chickenpox, measles, rubella and mumps, and the anti-HIV drug raltegravir stopped. An exception was made for drugs that do not have analogues.
- After the beginning of the Russian military invasion of Ukraine, several large foreign pharmaceutical companies limited their work in Russia. Yes, Gilead has suspended all non-life-saving drug operations. Pfizer, Bayer, Novartis, MSD, Sanofi and AbbVie continue to supply drugs, but have suspended investment or clinical research. The American pharmaceutical company Eli Lilly has decided to completely withdraw from the Russian market, transferring its business in Russia to its partner in Central and Eastern Europe, Swixx Biopharma.
[ad_2]
Original Source Link
